Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review-Reference-Cited by-同舟云学术

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review

Published:2024-01-31 Issue: Volume: Page:
ISSN:2056-5623
Container-title:Future Science OA
language:en
Short-container-title:Future Science OA

Author:

Christiansen Emilie Adrian¹,Kümler Iben²

Affiliation:

1. Faculty of Health & Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark

2. Department of Oncology, Herlev & Gentofte Hospital, Copenhagen University Hospital, Borgmester Ib Juuls vej 7, 2730 Herlev, Denmark

Abstract

Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this review we assess existing literature concerning real-world effectiveness of palbociclib. Survival outcomes in terms of progression-free survival and overall survival are discussed and compared among the included real-world studies and in relation to the phase III PALOMA trials.

Publisher

Informa UK Limited

Subject

Biotechnology

Link

https://www.future-science.com/doi/pdf/10.2144/fsoa-2023-0074

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. National Cancer Institute. Cancer stat facts: female breast cancer subtypes. https://seer.cancer.gov/statfacts/html/breast-subtypes.html

3. National Cancer Institute. Institute. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html

4. Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

5. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers